Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831998 | 0.85 | TRPC5 (0.36) | CA12CA1CA2CA9TRPC5 | |
| SCHEMBL20831522 | 0.81 | TRPC5 (0.56) | TRPC5ALDH1A1 | |
| SCHEMBL20832000 | 0.80 | CA12 (0.36) | CA12CA1CA2CA9TRPC5 | |
| SCHEMBL20831676 | 0.68 | TRPC5 (0.36) | TRPC5 | |
| SCHEMBL20831518 | 0.67 | TRPC5 (0.55) | TRPC5ALDH1A1 | |
| SCHEMBL20831517 | 0.65 | TRPC5 (0.56) | TRPC5ALDH1A1 | |
| SCHEMBL20831537 | 0.65 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL20831524 | 0.64 | TIPARP (0.56) | TRPC5MAPK14ALDH1A1 | |
| SCHEMBL20831621 | 0.63 | RAB9A (0.33) | CA12CA1CA2CA9DCTPP1 | |
| SCHEMBL20831960 | 0.62 | TRPC5 (0.61) | TRPC5ALDH1A1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | CA12 4343/4885CA1 4778/4885CA2 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.